Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

As part of its quest to “discover the science of humanity,” the Truveta Genome Project will gather the de-identified genetic data of tens of millions of consented volunteers, health data startup Truveta announced Jan. 13, 2025. (Credit: vatrushka67/Getty Images)

What if you could harness the power of everything that makes you biologically you—your sex, ancestry, genetic minutiae—to help accelerate drug discovery and prevent and cure diseases? The health care innovators behind the new Truveta Genome Project, billed as the world’s largest and most diverse genetic database, are hoping you will.

Truveta, a health data startup launched in 2020, announced the massive undertaking Jan. 13 along with biotech firm Illumina and the Regeneron Genetics Center, an arm of Fortune 500 company Regeneron Pharmaceuticals. Regeneron invested $119.5 million in Truveta’s Series C funding round, while Illumina chipped in $20 million. In addition, 17 of Truveta’s 30 partner health systems collectively contributed $180.5 million.